History
# Registration date Revision Id
2 2023-12-27, 1402/10/06 290502
1 2022-11-07, 1401/08/16 245053
Changes made to previous revision
This is the first revision

Protocol summary

Study aim
To compare the effectiveness of the total neoadjuvant therapy with standard approach in rectal adenocarcinoma patients
Design
This randomized and single-blind clinical trial with parallel and control groups will be conducted on 60 patients who will be randomly selected using the blocks.
Settings and conduct
Patients with rectal adenocarcinoma referring to Omid and Imam Reza Hospital, Mashhad, Iran are chosen as the participants of the study. In this single-blind study, sealed opaque envelopes will be used to conceal the sequencing. The person responsible for data collection is blind to group allocation and the type of treatment.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Patients with rectal adenocarcinoma based on pathological diagnosis; the zero to two level of Eastern Cooperative Oncology Group (ECOG); healthy functioning bone marrow; healthy functioning liver; healthy functioning kidneys. Exclusion criteria: Having simultaneous adenocarcinoma in other areas of the colon; having metastasis; history of previous malignancy; history of chemotherapy; history of pelvic radiotherapy; having inflammatory intestinal disease; having bilateral hip prosthesis; having allergic to 5-fluorouracil and its other derivatives; having allergic to oxaliplatin.
Intervention groups
In the intervention group, the patient will receive neoadjuvant treatment with pelvic radiotherapy along with capecitabine capsule, then neoadjuvant chemotherapy with FOLFOX or CapOx regimen, and finally definitive surgery. In the control group, the patient will undergo standard treatment in the form of first neoadjuvant treatment by pelvic radiotherapy with capecitabine capsules, then definitive surgery and finally adjuvant chemotherapy with FOLFOX or CapOx regimen.
Main outcome variables
Evaluation and comparison of the pathological complete response, local recurrence and distant metastasis

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20220723055527N1
Registration date: 2022-11-07, 1401/08/16
Registration timing: prospective

Last update: 2022-11-07, 1401/08/16
Update count: 1
Registration date
2022-11-07, 1401/08/16
Registrant information
Name
Fereshteh Foroughi Pordanjani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 51 3833 0626
Email address
foroughifrshte@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2022-12-11, 1401/09/20
Expected recruitment end date
2023-09-22, 1402/06/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
A clinical trial to compare the effectiveness of the total neoadjuvant therapy with standard approach in rectal adenocarcinoma patients
Public title
The effectiveness of the total neoadjuvant therapy in in rectal adenocarcinoma patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients with rectal adenocarcinoma based on pathological diagnosis The zero to two level of Eastern Cooperative Oncology Group (ECOG) Healthy functioning bone marrow Healthy functioning liver Healthy functioning kidneys
Exclusion criteria:
Having simultaneous adenocarcinoma in other areas of the colon Having metastasis History of previous malignancy History of chemotherapy History of pelvic radiotherapy Having inflammatory intestinal disease Having bilateral hip prosthesis Having allergic to 5-fluorouracil and its other derivatives Having allergic to oxaliplatin
Age
No age limit
Gender
Both
Phase
1-2
Groups that have been masked
  • Outcome assessor
Sample size
Target sample size: 60
Randomization (investigator's opinion)
Randomized
Randomization description
In this study, we will use the restricted randomization method of block randomization base on statistical analysis system (SAS), computer software. All blocks are the same size, and in this two-group experiment we will have 6 blocks (including 3 participants in the intervention group and 3 participants in the control group). Random allocation software software is also used to randomize random sequence production software (Random allocation software). To conceal, we use Allocation concealment, which refers to the method used to perform a random sequence on study participants, so that the assigned group is not identified before the individual is assigned. Using non-transparent envelopes sealed with random sequences (Sequentially numbered, sealed, opaque envelopes). They are placed in order. In order to maintain the random sequence, numbering is done on the outer surface of the envelopes in the same way. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants in the study, one of the envelopes of the letter will be opened in order and the assigned group of the participant will be revealed.
Blinding (investigator's opinion)
Single blinded
Blinding description
The data analyzer does not know which groups are located. The statistician will receive questionnaires as anonymously and in form A and B, and he/she does not know which are received the total neoadjuvant therapy or standard approach.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Mashhad University of Medical Sciences
Street address
Vice Chancellor for Research, Mashhad University of Medical Sciences, Ghoreishi building, Daneshgah Street
City
Mashhad
Province
Razavi Khorasan
Postal code
9195965919
Approval date
2022-04-19, 1401/01/30
Ethics committee reference number
IR.MUMS.MEDICAL.REC.1401.053

Health conditions studied

1

Description of health condition studied
Rectal adenocarcinoma
ICD-10 code
C20
ICD-10 code description
Malignant neoplasm of rectum

Primary outcomes

1

Description
The pathological complete response
Timepoint
One week after surgery
Method of measurement
Based on surgical pathology report

2

Description
Local recurrence
Timepoint
One year after intervention
Method of measurement
Pelvic computed tomography (CT) scan and colonoscopy

3

Description
Distant metastasis
Timepoint
One year after intervention
Method of measurement
Abdominal and pelvic CT scan

Secondary outcomes

1

Description
Complications of treatment
Timepoint
One, two and three weeks after treatment
Method of measurement
Based on the Common Terminology Criteria for Adverse Events (CTCAE)

Intervention groups

1

Description
Intervention group: The intervention group will first receive neoadjuvant treatment via pelvic radiotherapy with capecitabine tablets, then neoadjuvant chemotherapy with FOLFOX or CapOx regimen, and finally definitive surgery.
Category
Treatment - Drugs

2

Description
Control group: The control group will receive standard treatment in the form of neoadjuvant treatment via pelvic radiotherapy with capecitabine tablets, then definitive surgery and finally adjuvant chemotherapy with FOLFOX or CapOx regimen.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Omid hospital
Full name of responsible person
Fereshteh Foroughi Pordanjani
Street address
Omid Hospital, Al-Nandasht Square, Kooh Sangi Street
City
Mashhad
Province
Razavi Khorasan
Postal code
9176613775
Phone
+98 51 3833 0626
Email
foroughifreshte@gmail.com

2

Recruitment center
Name of recruitment center
Imam Reza Hospital
Full name of responsible person
Fereshteh Foroughi Pordanjani
Street address
Imam Reza Hospital, Imam Reza Square, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9137913316
Phone
+98 51 1761 5063
Email
foroughifrshte@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Mohsen Tafaghodi
Street address
Vice Chancellor for Research, Mashhad University of Medical Sciences, Ghoreishi building, Daneshgah Street
City
Mashhad
Province
Razavi Khorasan
Postal code
9138813944
Phone
+98 51 3841 1538
Email
vcresearch@mums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Mashhad University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Fereshteh Foroughi Pordanjani
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Radiology
Street address
Omid Hospital, Al-Nandasht Square, Kooh Sangi Street
City
Mashhad
Province
Razavi Khorasan
Postal code
9176613775
Phone
+98 51 3833 0626
Email
foroughifrshte@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Fereshteh Foroughi Pordanjani
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Radiology
Street address
Omid Hospital, Al-Nandasht Square, Kooh Sangi Street
City
Mashhad
Province
Razavi Khorasan
Postal code
9176613775
Phone
+98 51 3833 0626
Email
foroughifrshte@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Fereshteh Foroughi Pordanjani
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Radiology
Street address
Omid Hospital, Al-Nandasht Square, Kooh Sangi Street
City
Mashhad
Province
Razavi Khorasan
Postal code
9176613775
Phone
+98 51 3833 0626
Email
foroughifrshte@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
In our study none of the personal data of patients will be shared. Only data that are related to outcomes of intervention will be shared.
When the data will become available and for how long
6 months after publishing the results
To whom data/document is available
The research data is exclusively accessible to the researchers working at universities and centers for scientific research.
Under which criteria data/document could be used
The research data is exclusively accessible to the researchers working at universities and centers for scientific research.
From where data/document is obtainable
Fereshteh Foroughi Pordanjani provides the data analysis to the applicants via email: foroughifrshte@gmail.com
What processes are involved for a request to access data/document
Applicants can send emails to him and receive a response within a week.
Comments
Loading...